Emerging role of epigenetics in systemic sclerosis pathogenesis

Genes and Immunity

Volumn 15, Issue 7, 2014, Pages 433-439

  Ciechomska, M ^a   Van Laar, J M ^a   O'Reilly, S ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BELINOSTAT; ENTINOSTAT; LONG UNTRANSLATED RNA; MICRORNA; PANOBINOSTAT; PIVALOYLOXYMETHYL BUTYRATE; ROMIDEPSIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

AUTOIMMUNE DISEASE; BREAST CANCER; DNA METHYLATION; EPIGENETICS; HISTONE MODIFICATION; HUMAN; INFLAMMATORY DISEASE; LEUKEMIA; LIVER CELL CARCINOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID LEUKEMIA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PATHOGENESIS; REVIEW; RHEUMATIC DISEASE; SYSTEMIC SCLEROSIS; T CELL LYMPHOMA; THROMBOCYTHEMIA; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MICRORNAS; RNA, LONG NONCODING; SCLERODERMA, SYSTEMIC;

EID: 84908235099     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2014.44     Document Type: Review

References (66)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-567.
2. O'Reilly S, Ciechomska M, Cant R, Hügle T, van Laar JM. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012; 23: 99-107.
3. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
5. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403: 901-906.
6. Han J, Lee Y, Yeom K-H, Nam J-W, Heo I, Rhee J-K et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 2006; 125: 887-901.
7. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655.
8. Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010; 62: 1733-1743.
9. Roderburg C, Urban G-W, Bettermann K, Vucur M, Zimmermann H, Schmidt S et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53: 209-218.
10. Xiao J, Meng X-M, Huang XR, Chung ACK, Feng Y-L, Hui DSC et al. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther 2012; 20: 1251-1260.
11. Kawashita Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N et al. Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci 2011; 61: 67-69.
12. Ciechomska M, O'Reilly S, Suwara MI, van Laar JM. miR29a targets TAB1 gene and regulates TIMP-1 in systemic sclerosis. Arthritis Rheum 2014 (submitted).
13. Pottier N, Maurin T, Chevalier B, Puisségur M-P, Lebrigand K, Robbe-Sermesant K et al. Identification of keratinocyte growth factor as a target of microRNA-155 in lung fibroblasts: implication in epithelial-mesenchymal interactions. PLoS One 2009; 4: e6718.
14. Makino K, Jinnin M, Kajihara I, Honda N, Sakai K, Masuguchi S et al. Circulating miR-142-3p levels in patients with systemic sclerosis. Clin Exp Dermatol 2012; 37: 34-39.
15. Sakoguchi A, Jinnin M, Makino T, Kajihara I, Makino K, Honda N et al. The miR-146a rs2910164 C/G polymorphism is associated with telangiectasia in systemic sclerosis. Clin Exp Dermatol 2013; 38: 99-100.
16. Sing T, Jinnin M, Yamane K, Honda N, Makino K, Kajihara I et al. microRNA-92a expression in the sera and dermal fibroblasts increases in patients with scleroderma. Rheumatology (Oxford) 2012; 51: 1550-1556.
17. Honda N, Jinnin M, Kajihara I, Makino T, Makino K, Masuguchi S et al. TGF-b-mediated downregulation of MicroRNA-196a Contributes to the constitutive upregulated type I collagen expression in scleroderma dermal fibroblasts. J Immunol 2012; 188: 3323-3331.
18. Kajihara I, Jinnin M, Yamane K, Makino T, Honda N, Igata T et al. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type I collagen expression in scleroderma fibroblasts. Am J Pathol 2012; 180: 703-714.
19. Carlson CB, Lawler J, Mosher DF. Thrombospondins: from structure to therapeutics. Cell Mol Life Sci 2008; 65: 672-686.
20. Etoh M, Jinnin M, Makino K, Yamane K, Nakayama W, Aoi J et al. microRNA-7 down-regulation mediates excessive collagen expression in localized scleroderma. Arch Dermatol Res 2013; 305: 9-15.
21. Honda N, Jinnin M, Kira-Etoh T, Makino K, Kajihara I, Makino T et al. miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the Induction of integrin b3. Am J Pathol 2013; 182: 206-216.
22. Hermann A, Gowher H, Jeltsch A. Biochemistry and biology of mammalian DNA methyltransferases. Cell Mol Life Sci 2004; 61: 2571-2587.
23. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69: 915-926.
24. Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2009; 60: 3613-3622.
25. Stanczyk J, Ospelt C, Karouzakis E, Filer A, Raza K, Kolling C et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011; 63: 373-381.
26. Bechtel W, McGoohan S, Zeisberg EM, Muller GA, Kalbacher H, Salant DJ et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16: 544-550.
27. Sanders YY, Ambalavanan N, Halloran B, Zhang X, Liu H, Crossman DK et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 525-535.
28. Altorok N, Tsou PS, Coit P, Khanna D, Sawalha AH. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann Rheum Dis 2014 (e-pub ahead of print 8 May 2014; doi:10.1136/annrheumdis-2014-205303).
29. Hügle T, O'Reilly S, Simpson R, Kraaij MD, Bigley V, Collin M et al. Tumor necrosis factor co-stimulated T-lymphocytes from patients with systemic sclerosis trigger collagen production in fibroblasts. Arthritis Rheum 2013; 65: 481-491.
30. Lei W, Luo Y, Yan K, Zhao S, Li Y, Qiu X et al. Abnormal DNA methylation in CD4\+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 2009; 38: 369-374.
31. Lian X, Xiao R, Hu X, Kanekura T, Jiang H, Li Y et al. DNA demethylation of CD40L in CD4\+ T cells from women with systemic sclerosis: a possible explanation for female susceptibility. Arthritis Rheum 2012; 64: 2338-2345.
32. Jiang H, Xiao R, Lian X, Kanekura T, Luo Y, Yin Y et al. Demethylation of TNFSF7 contributes to CD70 overexpression in CD4\+ T cells from patients with systemic sclerosis. Clin Immunol 2012; 143: 39-44.
33. Selmi C, Feghali-Bostwick CA, Lleo A, Lombardi SA, De Santis M, Cavaciocchi F et al. X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. Clin Exp Immunol 2012; 169: 253-262.
34. Dees C, Schlottmann I, Funke R, Distler A, Palumbo-Zerr K, Zerr P et al. The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis. Ann Rheum Dis 2014; 73: 1232-1239.
35. Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P, Zerr P et al. Activation of canonical Wnt signalling is required for TGF-b-mediated fibrosis. Nat Commun 2012; 3: 735.
36. Wang Y, Fan P-S, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-2279.
37. Watson CJ, Collier P, Tea I, Neary R, Watson JA, Robinson C et al. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Hum Mol Genet 2014; 23: 2176-2188.
38. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007; 150: 862-872.
39. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71: 424-431.
40. Rombouts K, Niki T, Greenwel P, Vandermonde A, Wielant A, Hellemans K et al. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-b1-induced fibrogenesis in skin fibroblasts. Exp Cell Res 2002; 278: 184-197.
41. Ghosh AK, Mori Y, Dowling E, Varga J. Trichostatin A blocks TGF-b-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun 2007; 354: 420-426.
42. Huber LC, Distler JHW, Moritz F, Hemmatazad H, Hauser T, Michel BA et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007; 56: 2755-2764.
43. Hemmatazad H, Rodrigues HM, Maurer B, Brentano F, Pileckyte M, Distler JHW et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum 2009; 60: 1519-1529.
44. Krämer M, Dees C, Huang J, Schlottmann I, Palumbo-Zerr K, Zerr P et al. Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis. Ann Rheum Dis 2013; 72: 614-620.
45. Zhou Q, Chung AC, Huang XR, Dong Y, Yu X, Lan HY. Identification of novel long noncoding RNAs associated with TGF-beta/Smad3-mediated renal inflammation and fibrosis by RNA sequencing. Am J Pathol 2014; 184: 409-417.
46. Song X, Cao G, Jing L, Lin S, Wang X, Zhang J et al. Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary fibrosis. J Cell Mol Med 2014 (e-pub ahead of print 6 April 2014; doi:10.1111/jcmm.12243).
47. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K et al. Treatment of HCV infection by targeting microRNA. New Engl J Med 2013; 368: 1685-1694.
48. Liu N, He S, Ma L, Ponnusamy M, Tang J, Tolbert E et al. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS ONE 2013; 8: e54001.
49. Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 2012; 18: 1369-1377.
50. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85-94.
51. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066.
52. Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma 2014 (e-pub ahead of print 24 February 2014; doi:10.3109/10428194.2013.877134).
53. Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012; 30: 3361-3367.
54. Dizon DS, Damstrup L, Finkler NJ, Lassen U, Celano P, Glasspool R et al. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer 2012; 22: 979-986.
55. Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol 2013; 161: 68-75.
56. DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol 2013; 162: 326-335.
57. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-339.
58. Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol 2013; 31: 2128-2135.
59. Spigel DR, Burris 3rd HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2582-2589.
60. Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J et al. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Br J Cancer 2012; 106: 77-84.
61. Haigentz Jr M, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncol 2012; 48: 1281-1288.
62. Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol 2011; 13: 509-516.
63. Raffoux E, Cras A, Recher C, Boelle PY, de Labarthe A, Turlure P et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget 2010; 1: 34-42.
64. Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK et al. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol 2013; 71: 115-121.
65. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol 2014; 73: 495-501.
66. Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R et al. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 2004; 45: 381-386.